Paper40367177
Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy.
Zhang H and 8 others. Sci Adv, 2025. Cited by 59 papers, by iCite.
Cite this record
ConductScience Library. Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy. Papers, record 40367177. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40367177
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ferroptosis | Major topic |
| Neoplasms | Major topic |
| Photothermal Therapy | Major topic |
| Nanoparticles | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Cell Line, Tumor | |
| Apoptosis |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35239514 | Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. | J Clin Invest | 2022 | https://conductscience.org/library/papers/35239514 | PubMed |
| 2 | 29417106 | Nanoparticle-triggered in situ catalytic chemical reactions for tumour-specific therapy. | Chem Soc Rev | 2018 | https://conductscience.org/library/papers/29417106 | PubMed |
| 3 | 37822154 | Mild-Photothermal Effect Induced High Efficiency Ferroptosis-Boosted-Cuproptosis Based on Cu2 O@Mn3 Cu3 O8 Nanozyme. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/37822154 | PubMed |
| 4 | 31990409 | Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications. | Adv Mater | 2020 | https://conductscience.org/library/papers/31990409 | PubMed |
| 5 | 34160201 | Upconverted Metal-Organic Framework Janus Architecture for Near-Infrared and Ultrasound Co-Enhanced High Performance Tumor Therapy. | ACS Nano | 2021 | https://conductscience.org/library/papers/34160201 | PubMed |
| 6 | 23890059 | Oncology meets immunology: the cancer-immunity cycle. | Immunity | 2013 | https://conductscience.org/library/papers/23890059 | PubMed |
| 7 | 32929201 | PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. | Nat Cell Biol | 2020 | https://conductscience.org/library/papers/32929201 | PubMed |
| 8 | 34865269 | Guiding Transition Metal-Doped Hollow Cerium Tandem Nanozymes with Elaborately Regulated Multi-Enzymatic Activities for Intensive Chemodynamic Therapy. | Adv Mater | 2022 | https://conductscience.org/library/papers/34865269 | PubMed |
| 9 | 36995655 | Ultra-Small High-Entropy Alloy Nanoparticles: Efficient Nanozyme for Enhancing Tumor Photothermal Therapy. | Adv Mater | 2023 | https://conductscience.org/library/papers/36995655 | PubMed |
| 10 | 28516983 | Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. | Chem Soc Rev | 2017 | https://conductscience.org/library/papers/28516983 | PubMed |
| 11 | 33420008 | Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. | Nat Commun | 2021 | https://conductscience.org/library/papers/33420008 | PubMed |
| 12 | 33522578 | Metformin induces ferroptosis by targeting miR-324-3p/GPX4 axis in breast cancer. | Acta Biochim Biophys Sin (Shanghai) | 2021 | https://conductscience.org/library/papers/33522578 | PubMed |
| 13 | 27668797 | Nanomedicine: An iron age for cancer therapy. | Nat Nanotechnol | 2016 | https://conductscience.org/library/papers/27668797 | PubMed |
| 14 | 36527888 | Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. | Drug Resist Updat | 2023 | https://conductscience.org/library/papers/36527888 | PubMed |
| 15 | 35154485 | Engineered extracellular vesicle-based sonotheranostics for dual stimuli-sensitive drug release and photoacoustic imaging-guided chemo-sonodynamic cancer therapy. | Theranostics | 2022 | https://conductscience.org/library/papers/35154485 | PubMed |
| 16 | 33789692 | Ultrasound targeted microbubble destruction combined with Fe-MOF based bio-/enzyme-mimics nanoparticles for treating of cancer. | J Nanobiotechnology | 2021 | https://conductscience.org/library/papers/33789692 | PubMed |
| 17 | 32312987 | Transformable hybrid semiconducting polymer nanozyme for second near-infrared photothermal ferrotherapy. | Nat Commun | 2020 | https://conductscience.org/library/papers/32312987 | PubMed |
| 18 | 24943004 | Solvothermal synthesis of ternary Cu2 MoS4 nanosheets: structural characterization at the atomic level. | Small | 2014 | https://conductscience.org/library/papers/24943004 | PubMed |
| 19 | 34932846 | Coordinating the Mechanisms of Action of Ferroptosis and the Photothermal Effect for Cancer Theranostics. | Angew Chem Int Ed Engl | 2022 | https://conductscience.org/library/papers/34932846 | PubMed |
| 20 | 35028603 | Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice. | Cell Rep Med | 2021 | https://conductscience.org/library/papers/35028603 | PubMed |
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 59 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42862494 | Copper single-atom carbon dots hydrogel resets oxidative and immune homeostasis for rheumatoid arthritis therapy. | Discov Nano | 2026 | https://conductscience.org/library/papers/42862494 | PubMed |
| 42860524 | An ATP7A-Mediated Endogenous Regulation Bio-Clay Enzyme Enables Self-Amplified Copper Accumulation for Immunogenic Pyrop. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42860524 | PubMed |
| 42846706 | Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy. | Biomater Res | 2026 | https://conductscience.org/library/papers/42846706 | PubMed |
| 42699616 | Photocontrolled nanosystem potentiates photo-chemoimmunotherapy against TNBC by integrating apoptosis/ferroptosis/ pyroptosis and STING activation. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42699616 | PubMed |
| 42645179 | Experimental Detection Methods and Clinical Translational Challenges of Disulfidptosis in Cancer. | Cells | 2026 | https://conductscience.org/library/papers/42645179 | PubMed |
| 42502487 | Precise Catalysis and Immune Activation: New Strategies for Tumor Immunotherapy with Cascade Nanozymes. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42502487 | PubMed |
| 42473554 | Nanozyme-Driven Ferroptosis-Cuproptosis Interplay in Lung Cancer. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42473554 | PubMed |
| 42467272 | Bacteria mediated tumor therapy recent advances challenges and future perspectives. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42467272 | PubMed |
| 42454093 | Bimetallic nanozymes with galvanic cell effects eradicate intratumoral bacteria and tumor cells to overcome drug resistance and potentiate antitumor immune responses for tumor therapy. | Bioact Mater | 2026 | https://conductscience.org/library/papers/42454093 | PubMed |
| 42436485 | A novel pH-responsive nanoreactor for pyroptosis induction: multifaceted ROS amplification drives potent immunotherapy against triple-negative breast cancer. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42436485 | PubMed |
| 42382257 | Photo-responsive nanozymes: from photocatalytic mechanisms to precision therapy. | Front Chem | 2026 | https://conductscience.org/library/papers/42382257 | PubMed |
| 42376249 | Recent advances in engineered nanozymes for precision lung cancer therapy. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42376249 | PubMed |
| 42374476 | Targeting AIF to trigger RIPKs/MLKL necroptosis: a disulfiram-based strategy to reverse paclitaxel resistance in ovarian cancer. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42374476 | PubMed |
| 42316280 | Chemotactic Gold Nanozyme-Powered Flasklike Pentosan Nanobots for Tumor-Specific Drug Delivery. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42316280 | PubMed |
| 42178870 | From Cold to Hot: Nanozyme-Based Strategies for Reprogramming the Tumour Immunoenvironment. | Cell Prolif | 2026 | https://conductscience.org/library/papers/42178870 | PubMed |
| 42178559 | Self-fueling catalysis-driven membrane destabilization triggers CSC-enriched tumors ablation. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42178559 | PubMed |
| 42168999 | A multimodal ROS generation and bimodal ferroptosis and cuproptosis self-reinforced strategy for effective bone metastases therapy. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42168999 | PubMed |
| 42160094 | Bandgap-Engineered PtxTey:Ag2Te Composite Quantum Dots Enable Programmable NIR-II Imaging and Photothermal-Immune Synergistic Therapy. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42160094 | PubMed |
| 42151972 | A MOF-in-MOF nanoplatform for photothermal/chemodynamic therapy that enhances antitumor immunity through targeted suppression of the COX-2/PGE2 axis. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42151972 | PubMed |
| 42144539 | Piezoelectric Nanozymes With Acoustically Rejuvenated Catalytic Activities Rewire Lipid Metabolism for Two-Pronged Ferroptotic Therapy. | Angew Chem Int Ed Engl | 2026 | https://conductscience.org/library/papers/42144539 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40367177
GET https://conductscience.org/api/papers/v1/40367177/references?page=2